Gender-based differences in platelet function and platelet reactivity to P2Y$_{12}$ inhibitors

Marco Ranucci$^{1,*}$, Tommaso Aloisio$^1$, Umberto Di Dedda$^1$, Lorenzo Menicanti$^2$, Carlo de Vincentiis$^2$, Ekaterina Baryshnikova$^1$, for the Surgical and Clinical Outcome REsearch (SCORE) group$^\dagger$

1 Department of Cardiothoracic, Vascular Anaesthesia and Intensive Care, IRCCS Policlinico San Donato, Milan, Italy, 2 Department of Cardiac Surgery, IRCCS Policlinico San Donato, Milan Italy

$^\dagger$Membership of the Surgical and Clinical Outcome REsearch (SCORE) group is provided in the Acknowledgments.

*cardioanesthesia@virgilio.it

Abstract

**Background**

Gender influences platelet biology. Women have a larger platelet count, but gender-based differences in platelet function remain debated. We performed a study addressing gender-based differences in platelet function using point-of-care platelet function tests (PFT).

**Methods**

The patient population consisted of 760 cardiac surgery patients where preoperative PFT (multiple-electrode aggregometry [MEA]) were available. Platelet count and function at the ADP test and TRAP test were compared in the overall population and separately in patients with or without residual effects of P2Y$_{12}$ inhibitors.

**Results**

Women had a significantly ($P = 0.001$) higher platelet count but a non-significantly higher platelet reactivity to ADP. In clopidogrel-treated patients, the platelets ADP reactivity was significantly ($P = 0.031$) higher in women, and platelet count was the main determinant of platelet hyper-reactivity. Within patients under full clopidogrel effects, women with a platelet count $\geq 200,000$ cells/$\mu$L had a significantly ($P = 0.023$) higher rate of high-on-treatment platelet reactivity (HTPR, 45.5%) with respect to males with a platelet count $< 200,000$ cells/$\mu$L (11.9%), with a relative risk of 6.2 (95% confidence interval 1.4–29).

**Conclusions**

Our findings confirm that women have a larger platelet count than men, and that this is associated to a trend towards a higher platelet reactivity. HTPR is largely represented in women with a high platelet count. This generates the hypothesis that women requiring P2Y$_{12}$ inhibitors could potentially benefit from larger doses of drug or should be treated with anti-platelet agents with a low rate of HTPR.
Introduction

Platelet biology is influenced by gender [1–3]. Platelet count is higher in women, and a number of studies have highlighted that platelet activation is enhanced [4–6], due to a greater expression of many surface receptors [7, 8].

Women are more susceptible to aspirin resistance, with a rate of major coronary events and ischemic stroke under aspirin treatment that is not different with respect to controls [9, 10].

In patients under double anti-platelet therapy (DAPT) the interaction between gender and efficacy was absent [11, 12] or only demonstrated a trend towards a lower efficacy in women [13].

Most of the studies investigating gender-dependent differences in platelet function were based on platelet count only, obsolete tests (bleeding time), light-transmission aggregometry, optical aggregometry, or sophisticated laboratory tests. However, the recent randomized controlled trials investigating the efficacy of different P2Y₁₂ inhibitors used point-of-care (POC) platelet function tests (PFT) to address platelet reactivity and high on-treatment platelet reactivity (HTPR) [14–16]. Overall, among the phenotypical factors leading to HTPR in patients under clopidogrel, gender female is considered [17].

A large study addressing gender-based differences in platelet function and platelet reactivity to P2Y₁₂ inhibitors based on the currently available POC PFT is presently lacking. The present study is a large retrospective analysis of platelet count and function in cardiac surgery patients before surgery, using a POC PFT, and aimed to determine gender-based differences.

Materials and methods

Study design

The present study is a post-hoc analysis of three previous (two retrospective in 2012–2013 and one prospective in 2016–2017) studies performed at our institution between 2010 and 2017 [18–20]. In these studies, patients scheduled for cardiac operations were investigated with standard laboratory tests and POC PFT before surgery. Data from these studies were utilized to investigate the hypothesis that gender-based differences exist in platelet reactivity in patients with or without DAPT. The three studies were approved by the local Ethics committee that waived the need for an informed consent for the two retrospective studies (Ethics Committee Melegnano, approval number 2702, 15/2/2012) and requested a written informed consent for the prospective study (Ethics Committee San Raffaele Hospital, approval number 137/INT/2016). Data from the three studies were pooled together and differences in platelet count and function between women and male were analyzed separately for patients free from the effects of P2Y₁₂ inhibitors or under full/residual effects of these drugs.

This work was supported by the IRCCS Policlinico San Donato which is a Clinical Research Hospital recognized and funded by the Italian Ministry of Health.

Patient population

The overall patient population included 760 adult cardiac surgery patients, of whom 440 were free from the effects of P2Y₁₂ inhibitors (ticlopidine, clopidogrel, prasugrel or ticagrelor) and 320 were assessed within 6 days from P2Y₁₂ inhibitors discontinuation.

The only exclusion criterion was the evidence of congenital platelet disease of any kind.

Data collection and definitions

The following data were collected: demographics (age, gender, weight, height, and body mass index [BMI]); obesity (BMI > 30 kg/m²); heart function details; presence of coronary artery
disease; co-morbidities; use of P2Y\textsubscript{12} inhibitors (with type of drug); days of discontinuation of these drugs; type of cardiac surgery; serum creatinine level (mg/dL); bilirubin level (mg/dL); hematocrit (%). For patients under DAPT, the standard dose was used (ticlopidine 250 mg twice a day; clopidogrel 75 mg/day, prasugrel 10 mg/day reduced to 5 mg if weight < 60 kg; ticagrelor 90 mg twice a day).

Platelet function tests were performed at variable times before surgery, from 6 days to immediately before the induction of anesthesia, using a multiple-electrode aggregometry (MEA, Multiplate, Roche Diagnostics, Indianapolis, IN) and are explained in a dedicated section.

**Platelet function tests**

An amount of 3 mL of blood was drawn from a venous line and collected in hirudin-coated tubes provided by the manufacturer. Platelet aggregation testing on the MEA analyzer was performed as follows. Briefly, 300 $\mu$L of whole blood were added to an equal amount of preheated saline solution and platelet aggregation was tested after specific activation with adenosine diphosphate (ADP, ADPtest, 6.5 $\mu$M final concentration). P2Y\textsubscript{12} receptors are inhibited by direct ADP receptor inhibitors (clopidogrel, ticlopidine, prasugrel and ticagrelor). Platelet aggregation was electronically measured for 6 minutes and expressed as units of area under the curve plotted over time (U). Normal reference range for ADPtest is 57–113 (U). HTPR was defined according to a recent consensus paper [21] as a MEA ADPtest value > 46 U in patients under non-discontinued treatment with P2Y\textsubscript{12} inhibitors. This cut-off value was increased to > 60 U for a discontinuation time within 12 and 24 hours before the PFT.

All the test were performed by a dedicated biologist (E.B.) in the hemostasis/coagulation laboratory of our institution.

**Statistics**

For the purpose of this study, the dependent variable were (i) the platelet reactivity at the MEA ADPtest and (ii) the HTPR rate. The main independent variable was gender. Other potential determinants of the dependent variables were those listed in data collection and definitions section. Among them, platelet count was considered an important potential confounder of MEA ADPtest, and was included in adjusted models for platelet reactivity and HTPR rate.

Continuous variables are presented as median and interquartile range after verification of a non-normal distribution at the Kolmogorov-Smirnov test, and as number and percentage for categorical variables. Differences between continuous variables were tested with non-parametric tests. Differences in categorical variables were tested using a Pearson’s chi square, producing relative risk and 95% confidence interval. Linear regression models were applied to adjust for potential confounders the relationship between gender and platelet function. Logistic regression models with dichotomous dependent variable were used to identify the independent variables and to adjust for potential confounders, producing odds ratio with 95% confidence interval. A P value $< 0.05$ was considered significant for all the statistical tests. All the analyses were performed using computerized statistical packages (SPSS 13.0, IBM, Chicago, IL, GraphPad Prism 7.0, GraphPad Software, Inc., La Jolla, CA).

**Results**

The general characteristics and the platelet count and function data are presented in Table 1, separately for patients with or without residual effects of P2Y\textsubscript{12} inhibitors. Apart from the normal anthropometric differences, within patients free from P2Y\textsubscript{12} inhibitors women had a higher ejection fraction and NYHA class; a lower rate of stable coronary disease and diabetes;
| Variable                              | Patients free from P2Y12 inhibitors (N = 440) | Patients under or with residual effects of P2Y12 inhibitors (N = 320) |
|--------------------------------------|-----------------------------------------------|---------------------------------------------------------------------|
|                                      | Women (N = 146)                               | Men (N = 294)                                                      | P       |
|                                      | Age (years)                                   | Weight (kgs)                                                       | Height (cms)                              |
|                                      | 73 (61–78)                                    | 62 (56–70)                                                        | 160 (156–165)                             | 0.001   |
|                                      | 68 (59–74)                                    | 78 (70–88)                                                        | 172 (168–178)                             | 0.001   |
|                                      | Weight (kgs)                                  | Height (cms)                                                      | BMI (23.8 (21.4–27.3)                      | 0.001   |
|                                      | 62 (56–70)                                    | 160 (156–165)                                                    | 0 (0–2)                                   | 0.001   |
|                                      | 68 (59–74)                                    | 172 (168–178)                                                    | 26 (23.9–29.3)                            | 0.001   |
|                                      | Weight (kgs)                                  | Height (cms)                                                      | BMI (26.4 (24.2–28.4)                      | 0.124   |
|                                      | 62 (56–70)                                    | 160 (156–165)                                                    | 26.4 (24.2–28.4)                          | 0.124   |
|                                      | 68 (59–74)                                    | 172 (168–178)                                                    | 26 (23.9–29.3)                            | 0.001   |
|                                      | Weight (kgs)                                  | Height (cms)                                                      | BMI (30.9 (28.6–33.1)                      | 0.107   |
|                                      | 62 (56–70)                                    | 160 (156–165)                                                    | 30.9 (28.6–33.1)                          | 0.107   |
|                                      | 68 (59–74)                                    | 172 (168–178)                                                    | 30.9 (28.6–33.1)                          | 0.107   |
| Obese (%)                            | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 24 (16.4)                                     | 26 (18.8)                                                         | 0.231   |
| Ejection fraction (%)                | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 55 (50–62)                                    | 55 (47–60)                                                        | 0.019   |
| New York Heart Association class     | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 0 (0–2)                                       | 0 (0–2)                                                           | 0.005   |
| Stable coronary artery disease       | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 42 (28.8)                                     | 149 (50.7)                                                        | 0.001   |
| Unstable angina                     | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 0 (0)                                         | 0 (0)                                                             | N/A    |
| Congestive heart failure             | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 14 (9.6)                                      | 19 (6.5)                                                          | 0.241   |
| Chronic obstructive pulmonary disease| Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 12 (8.2)                                      | 18 (6.1)                                                          | 0.411   |
| Previous cerebrovascular accident    | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 6 (4.1)                                       | 9 (3.1)                                                           | 0.568   |
| Diabetes on medication              | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 17 (11.6)                                     | 58 (19.7)                                                         | 0.034   |
| Serum creatinine (mg/dL)             | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 1.0 (0.8–1.4)                                 | 1.2 (1.0–1.4)                                                     | 0.001   |
| Serum bilirubin (mg/dL)              | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 0.5 (0.5–0.6)                                 | 0.5 (0.5–0.5)                                                     | 0.039   |
| Hematocrit (%)                      | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 38 (34–40)                                    | 42 (39–44)                                                        | 0.001   |
| Platelet count (x 1,000 cells/μL)    | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 211 (173–266)                                 | 191 (158–225)                                                     | 0.001   |
| Platelet reactivity at ADP test (U)  | Women (N = 146)                               | Men (N = 294)                                                     | P       |
|                                      | 58 (45–74)                                    | 56 (39–70)                                                        | 0.085   |

(Continued)
a lower hematocrit, serum creatinine value, and a higher serum bilirubin value. With respect to the platelet-related parameters, women had a significantly (P = 0.001) higher platelet count and a non-significantly (P = 0.085) higher platelet reactivity to ADP.

Once adjusted for the platelet count, the ADP-dependent platelet reactivity lost even this non-significant trend for association with gender (regression coefficient 0.594, 95% confidence interval -3.87 to 4.96, P = 0.789), while platelet count was a significant determinant of platelet reactivity (regression coefficient 0.164, 95% confidence interval 0.132–0.195, P = 0.001).

Within patients under full or residual effects of P2Y$_{12}$ inhibitors, women demonstrated a larger obesity rate, a lower rate of stable coronary disease and a lower hematocrit value.

The higher platelet count in women was confirmed within this subgroup. Platelets ADP reactivity was non-significantly (P = 0.148) higher in women, and the rate of HTPR was similar in women and men. When the analysis was restricted to clopidogrel-treated patients, the platelets ADP reactivity was significantly (P = 0.031) higher in women.

The values of ADP reactivity test as a function of the time of discontinuation are shown in Fig 1. This analysis is restricted to patients receiving clopidogrel within 6 days before the PFT.

![Figure 1](https://doi.org/10.1371/journal.pone.0225771.g001)

**Table 1.** (Continued)

| High on treatment platelet reactivity** | 7 (35) | 15 (18.1) | 0.097 |

Data are median (interquartile range) or number (%). ADP: adenosindiphosphate

* Clopidogrel-treated patients only

** No discontinuation or discontinuation time ≤ 24 hours before the test (N = 103, 20 women and 83 men).

[https://doi.org/10.1371/journal.pone.0225771.t001](https://doi.org/10.1371/journal.pone.0225771.t001)
Within patients on full clopidogrel treatment or who discontinued clopidogrel within 24 hours before the PFT, the ADP-dependent reactivity of platelets was significantly (P = 0.014) higher in women (median 46 U, interquartile range 36–69) than in men (median 32 U, interquartile range 16–55). Once corrected for platelet count, gender female demonstrated a non-significant (P = 0.061) trend towards a higher platelet reactivity, while platelet count was significantly (P = 0.008) associated with a higher platelet reactivity. In this subgroup, there was a non-significant (P = 0.097) higher rate of HTPR in women (relative risk 2.44, 95% confidence interval 0.83–7.16).

Factors with a P value < 0.1 were included in a multivariable analysis: for this purpose, continuous variables were dichotomized according to the median value. Within this model, factors independently associated with HTPR were unstable angina (odds ratio 6.0, 95% confidence interval 1.16–31, P = 0.033) and chronic obstructive pulmonary disease (odds ratio 7.2, 95% confidence interval 1.42–36, P = 0.017). Gender female was not independently associated with HTPR (odds ratio 2.14, 95% confidence interval 0.83–7.16, P = 0.253). A second model inclusive of gender female and platelet count only yielded an odds ratio for HTPR of 2.40 (95% confidence interval 0.80–7.20, P = 0.118).

The patient population was divided into four classes depending on gender and platelet count below or above the value of 200,000 cells/μL, that corresponds to the median value in the overall population (Fig 2). Female patients with a platelet count ≥ 200,000 cells/μL had the higher rate of HTPR (45.5%) with a significant (P = 0.023) difference with respect to males.

---

Fig 2. High-on-treatment platelet reactivity (HTPR) in women and men under full clopidogrel effects, as a function of platelet count.

PLT: platelet.

https://doi.org/10.1371/journal.pone.0225771.g002
with a platelet count < 200,000 cells/μL (11.9%), with a relative risk of 6.2 (95% confidence interval 1.4–29).

**Discussion**

The main results of the present study may be summarized as follows: (i) in patients free from the effects of P2Y₁₂ inhibitors, gender female is associated with a higher platelet count but not with a higher ADP-dependent platelet reactivity; (ii) in patients under full or residual effects of P2Y₁₂ inhibitors of any kind, the ADP-dependent platelet reactivity was not significantly different between women and men; and (iii) in patients under full or residual effects of clopidogrel, the ADP-dependent platelet reactivity was significantly higher in women, especially in those who discontinued the drug within 24 hours before the test; however, only a trend remained after correction for platelet count; (iv) in patients who discontinued the P2Y₁₂ inhibitors within 24 hours before the PFT, after correction for the potential confounders, the risk of HTMR was double in women vs. men, however without reaching a statistical significance. A combination of gender female and platelet count $\geq$ 200,000 cells/μL yielded a high risk of HTMR (45%).

Overall, our study seems to confirm a general trend towards a higher ADP-dependent platelet reactivity in women treated with P2Y₁₂ inhibitors and namely with clopidogrel, however raising the possibility that this finding is dependent on differences in platelet count rather than function. Multiple-electrode aggregometry is based on the ability of platelets to aggregate on electrical filaments and hence to increase the electrical impedance. The increase in electrical impedance is not only dependent on the quality of platelet aggregation, but even on the quantity of platelets involved in the process. Previous studies have highlighted that the results of MEA have a positive association with platelet count, regardless of platelet count value [22]. A high platelet count has been already identified as a factor leading to HTMR [17, 18]. Other
point-of-care tests of platelet function may have different associations with platelet count, but it is reasonable to hypothesize that thrombocytosis affects platelet function measurements.

Even considering the confounding effect of higher platelet counts, a signal towards a higher rate of HTPR in women remains: after correction for platelet count, the odds ratio for HTPR is more than double in females, lacking statistical significance due to the relatively low sample size (103 patients). The combination of gender female and a high platelet count carries a risk for HTPR that is largely higher than what reported in the existing Literature [17,18,21].

Data on the role of gender in the determinism of HTPR are presently scarce. A cohort study on 846 treated with prasugrel or clopidogrel identified gender as a covariate affecting platelet inhibition in a linear mixed-effect model comparing the maximum platelet aggregation and the inhibition of platelet aggregation between treatments over time points [23]. A recent Danish study on stroke patients treated with clopidogrel reports that patients with HTPR were 46% females vs. 39% in non-HTPR patients [24]. This difference is larger in a recent study where gender female was found in 29% of HTPR patients vs. 15% in non-HTPR patients [25].

\[ P2Y_{12} \]
inhibitors commonly used for DAPT belong to thienopyridines (ticlopidine, clopidogrel, prasugrel) which irreversibly block the ADP receptor, or cyclopentyl triazolopyrimidines, which exert a reversible inhibition (ticagrelor). Cilostazol is not used in coronary patients. HTPR has been described in about 25% of patients treated with clopidogrel [18], 10% of patients treated with prasugrel, and 2% in patients treated with ticagrelor [26]. Other differences among these drugs include a more rapid onset of action for prasugrel and ticagrelor vs. clopidogrel [27].

Studies investigating the effects of prasugrel and ticagrelor failed to detect gender-related differences in outcomes [11,12]. In these studies, the prevalence of gender female was between 25% and 28%. However, even if no differences in outcomes have been demonstrated, there are evidences that coronary patients under DAPT have different gender-based platelet reactivity and HTPR rate. In a recent study, Jastrzebka and associates found that women treated with a combination of aspirin and clopidogrel had a higher residual platelet reactivity than men, and a higher HTPR [28].

The physiological basis for a higher platelet reactivity in women, apart from their larger platelet count, has been hypothesized in previous studies. Platelets have estrogen receptors that inhibits platelet activation in pre-menopausal women [29]. This effect is lost in post-menopausal women (the large majority of our patient population). Additionally, estrogens are involved in prostacyclines synthesis and nitric oxide bioavalability [30], both factors blunting platelet aggregation. In pre-menopausal women, estrogen levels fluctuations may result in different levels of platelet reactivity.

As clopidogrel has to be metabolized by cytochrome P (CYP) enzymes, it is possible that there is an estrogen-dependent effect on CYP activity. Actually, there is an estrogen-dependent effect on cytochrome P450 3A (CYP3A) subfamily: in the endometrium, CYP3A4 and CYP3A43 are down-regulated by estrogen [31]. However, polymorphisms of CYP3A4 were not associated with treatment resistance when compared to responders to clopidogrel therapy [32].

In a study population similar to our study (coronary patients with stable angina) [28], the authors could find that in gender female the higher platelet reactivity while on DAPT with clopidogrel was associated with a pro-inflammatory profile, with higher levels of C-reactive protein and leukocytes.

There are limitations in our study. The first is the retrospective nature which did not allow us to address some possible confounders, like smoking habit. The second is the relatively low sample size with consequent no-significance of some potentially relevant trends. Finally, the great majority of our patients was treated with clopidogrel, which is a drug with a considerable
HTPR rate. It is possible that the results differ if tested in patients under P2Y\textsubscript{12} inhibitors with a lower rate of HTPR (prasugrel or ticagrelor).

Given these limitations, our study highlights that the subset of women with a high platelet count seems particularly susceptible to HTPR, at a rate (45\%) larger than the expected (25\% from the existing literature). This finding generates the hypothesis that this segment of patients, when requiring P2Y\textsubscript{12} inhibitors, could potentially benefit from larger doses or, more reasonably, be directly treated with drugs carrying the lower risk of HTPR (ticagrelor). Association with oral anti-factor X\textsubscript{a} drugs could be an additional option in patients requiring a prophylaxis of thrombotic events (atrial fibrillation). Further studies in these directions are warranted.

Supporting information

S1 Table. Original data.
(XLS)

Acknowledgments

The Surgical and Clinical Outcome Research (SCORE) Group joins a number of Researchers involved in Outcome Research at the IRCCS Policlinico San Donato. For the present study, the following members of the SCORE Group gave a contribution:

1. Marco Ranucci, MD, FESC, Department of Cardiothoracic, Vascular Anaesthesia and Intensive Care, IRCCS Policlinico San Donato, Milan, Italy
2. Tommaso Aloisio, MD, Department of Cardiothoracic, Vascular Anaesthesia and Intensive Care, IRCCS Policlinico San Donato, Milan, Italy
3. Umberto Di Dedda, MD, Department of Cardiothoracic, Vascular Anaesthesia and Intensive Care, IRCCS Policlinico San Donato, Milan, Italy
4. Lorenzo Menicanti, MD, Department of Cardiac Surgery, IRCCS Policlinico San Donato, Milan, Italy
5. Carlo de Vincentiis, MD, Department of Cardiac Surgery, IRCCS Policlinico San Donato, Milan, Italy
6. Ekaterina Baryshnikova, PhD (Biol), Department of Cardiothoracic, Vascular Anaesthesia and Intensive Care, IRCCS Policlinico San Donato, Milan, Italy

Author Contributions

Conceptualization: Marco Ranucci, Umberto Di Dedda.
Data curation: Ekaterina Baryshnikova.
Formal analysis: Marco Ranucci.
Investigation: Tommaso Aloisio, Ekaterina Baryshnikova.
Methodology: Marco Ranucci, Ekaterina Baryshnikova.
Supervision: Lorenzo Menicanti, Carlo de Vincentiis.
Writing – original draft: Marco Ranucci.
Writing – review & editing: Lorenzo Menicanti, Carlo de Vincentiis.

References

1. Patti G, De Caterina R, Abbate R, Andreotti F, Biasucci LM, Calabrò P, et al. Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A 'state-of-the-art' paper. Eur Heart J. 2014; 35:2213–2223. https://doi.org/10.1093/eurheartj/ehu279 PMID: 25024407

2. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature. 1975; 253:355–357. https://doi.org/10.1038/253355a0 PMID: 1110780

3. Stevens RF, Alexander MK. A sex difference in the platelet count. Br J Haematol. 1977; 37:295–300. https://doi.org/10.1111/j.1365-2141.1977.tb06847.x PMID: 603762

4. Segal JB, Moliterno AR. Platelet counts differ by sex, ethnicity, and age in the United States. Ann Epidemiol. 2006; 16:12

5. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost. 1997; 77:748–754. PMID: 9134654

6. Haque SF, Matsubayashi H, Izumi S, Sugi T, Arai T, Kondo A, et al. Sex difference in platelet aggregation detected by new aggregometry using light scattering. Endocr J. 2011; 48:33–41. https://doi.org/10.1507/endocrj.48.33 PMID: 21430101

7. Zwierzina WD, Kunz F, Kogelnik R, Herold M. Sex-related differences in platelet aggregation in native whole blood. Thromb Res. 1987; 48:161–171. https://doi.org/10.1016/0049-3848(87)90412-9 PMID: 21430101

8. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996; 334:1090–1094. PMID: 8598867

9. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373:1849–1860. https://doi.org/10.1016/S0140-6736(09)60503-1 PMID: 19482214
19. Ranucci M, Colella D, Baryshnikova E, Di Dedda U; Surgical and Clinical Outcome Research (SCORE) Group. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth. 2014; 113:970–976. https://doi.org/10.1093/bja/aeu315 PMID: 25209096

20. Ranucci M, Pistuddi V, Di Dedda U, Menicanti L, De Vincentis C, Baryshnikova E; Surgical and Clinical Outcome REsearch (SCORE) group. Platelet function after cardiac surgery and its association with severe postoperative bleeding: the PLATFORM study. Platelets. 2018; https://doi.org/10.1080/09537104.2018.1535706 PMID: 30365338

21. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013; 62:2261–2273. https://doi.org/10.1016/j.jacc.2013.07.101 PMID: 24076493

22. Ranucci M, Baryshnikova E, for The Surgical And Clinical Outcome Research Score Group. The interaction between preoperative platelet count and function and its relationship with postoperative bleeding in cardiac surgery. Platelets. 2017; 28:794–798. https://doi.org/10.1080/09537104.2017.1280148 PMID: 28277058

23. Li YG, Ni L, Brandt JT, Small DS, Payne CD, Ernest CS 2nd, et al. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets. 2009; 20:316–327. https://doi.org/10.1080/09537100903048317 PMID: 19637095

24. Rath CL, Rye Jørgensen N, Wienecke T. High On-Treatment Platelet Reactivity in Danish hyper-acute ischaemic stroke patients. Front Neurol. 2018; 9:712. https://doi.org/10.3389/fneur.2018.00712 PMID: 30210437

25. Musallam A, Orvin K, Perl L, Mosseri M, Arbel Y, Roguin A, et al. Effect of modifying antiplatelet treatment to Ticagrelor in high-risk coronary patients with low response to Clopidogrel (MATTIS). Can J Cardiol. 2016; 32:1246.e13–1246.e1

26. Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. J Thromb Haemost. 2015; 13:931–942. https://doi.org/10.1111/jth.12907 PMID: 25809392

27. Bavishi C, Panwar S, Messerli FH, Bangalore S. Meta-analysis of comparison of the newer oral P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with non-ST-elevation acute coronary syndrome. Am J Cardiol. 2015; 116:809–817. https://doi.org/10.1016/j.amjcard.2015.05.058 PMID: 26119555

28. Jastrzebska M, Marcinowksa Z, Oledzki S, Chelstowski K, Siennicka A, Klysz M, et al. Variable gender-dependent platelet responses to combined antiplatelet therapy in patients with stable coronary-artery disease. J Physiol Pharmacol 2018; 69; ePaub ahead of print.

29. Sowers MR, Matthews KA, Jannausch M, Randolph JF, McConnell D, Sutton-Tyrrell K, et al. Hemostatic factors and estrogen during the menopausal transition. J Clin Endocrinol Metab. 2005; 90:5942–5948. https://doi.org/10.1210/jc.2005-0591 PMID: 16105968

30. Caulin-Glaser T, Garcia-Cardena G, Sarrel P, Sessa WC, Bender JR. 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res. 1997; 81:885–892. https://doi.org/10.1161/01.res.81.5.885 PMID: 9351464

31. Williams ET, Leyk M, Wrighton SA, Davies PJA, Loose DS, Shipley GL, et al. Estrogen regulation of the Cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther. 2004; 311:728–735. https://doi.org/10.1124/jpet.104.068908 PMID: 15282264

32. Al-Husein BA, Al-Azzam SI, Alzoubi KH, Khabour OF, Nusair MB, Alzayadeen S. Investigating the effect of demographics, clinical characteristics, and polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on clopidogrel resistance. J Cardiovasc Pharmacol. 2018; 72:296–302. https://doi.org/10.1097/FJC.0000000000000627 PMID: 30422888